Enjoy complimentary customisation on priority with our Enterprise License!
The age-related macular degeneration market size is forecast to increase by USD 5.10 billion at a CAGR of 6.54% between 2023 and 2028. The Age-related Macular Degeneration (AMD) market is experiencing significant growth due to the high prevalence of this degenerative eye condition, particularly among the aging population. According to the World Health Organization, AMD is the leading cause of vision loss in individuals over 50 years old. This trend is expected to continue as the global population ages. Strategic alliances and collaborations among market traders to develop and treat AMD are also driving market growth. However, the lack of approved therapies for dry AMD, which accounts for approximately 80-90% of AMD cases, presents a major challenge to market growth. Despite this, ongoing research and development efforts are expected to lead to new treatment options and advancements in AMD diagnosis and management.
Age-related Macular Degeneration (AMD) is a leading cause of vision loss among the geriatric population, affecting an estimated 196 million people worldwide by 2020, according to the World Health Organization. AMD is characterized by the deterioration of the macula, a small area in the retina responsible for sharp, central vision. Wet AMD, a more severe form of the disease, is characterized by the growth of new blood vessels under the retina, which leak blood and fluid, causing vision loss. Pipeline valuation analysis reveals significant business possibilities in the AMD market with several pipeline drugs under development. Notable pipeline drugs include Eylea and Ranibizumab from Regeneron, Lucentis from Genentech, and Opt-302, KSI-301, RGX-314, Danicopan, and ALXN2040 from various pharmaceutical companies.
Unmet needs in the AMD market include the development of more effective and cost-effective treatment options. Current treatment options include anti-VEGF therapy, such as Eylea, Lucentis, and Ranibizumab, which target the VEGF protein that plays a role in the growth of new blood vessels. Vitamin supplements and lifestyle changes are also recommended for AMD management. The global AMD market is expected to grow significantly due to the increasing prevalence of AMD in the aging population and the unmet needs for effective and affordable treatment options.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The wet AMD segment is estimated to witness significant growth during the forecast period. Age-related Macular Degeneration (AMD) is a progressive eye condition characterized by damage to the macula, a small spot near the center of the retina responsible for sharp, central vision. Two forms of AMD exist: dry and wet. In wet AMD, abnormal blood vessels grow under the retina and macula, leading to vision loss. This condition, which accounts for only 10-15% of AMD cases, is characterized by the presence of blood or fluid under the macula, resulting in a dark spot in the center of the vision. The primary driver of growth in the AMD market is the increasing use of anti-Vascular Endothelial Growth Factor (VEGF) intravitreal injections, such as Lucentis (Ranibizumab) by Regeneron and Eylea (Aflibercept) by Bayer and Regeneron, for the treatment of wet AMD.
The US Food and Drug Administration (FDA) has approved these drugs, along with Macugen (Pegaptanib), for the treatment of this condition. The World Health Organization (WHO) reports that the geriatric population, the primary demographic affected by AMD, is projected to grow significantly, increasing the unmet needs in the AMD market and presenting significant business possibilities. Other therapeutic options include photodynamic therapy (PDT), laser photocoagulation, Avastin, Faricimab, Susvimo, Danicopan, ALXN2040, EG-301, and RGX-314. The AMD pipeline valuation analysis indicates ongoing clinical trials for various therapeutic approaches, including OPT-302, KSI-301, and Vitamin supplements, as well as lifestyle changes. Understanding the mechanisms of action, disease management, treatment usage patterns, and strategic competitor assessment are crucial for market characterization and clinical trial mapping in the AMD therapeutics market.
Symptoms and diagnosis of AMD include blurred vision, distorted shapes, difficulty recognizing faces, and a dark or empty area in the center of the vision. The AMD therapeutics market revenue is expected to grow significantly due to the increasing prevalence of this condition and the development of new therapeutic options.
Get a glance at the market share of various segments Request Free Sample
The wet AMD segment was valued at USD 10.19 billion in 2018 and showed a gradual increase during the forecast period.
North America is estimated to contribute 44% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
For more insights on the market share of various regions Request Free Sample
The Age-related Macular Degeneration (AMD) market is experiencing significant growth, particularly in North America, due to the increasing prevalence of this condition. With an estimated 20 million adults in the United States currently living with AMD, this number is projected to rise to 30 million by 2050. In Canada, nearly 200,000 new cases are diagnosed each year. The primary risk factor for AMD is age, with the risk increasing from 2% for individuals aged 50-59 to nearly 30% for those above 75. Neovascular AMD, a more advanced and damaging form of the disease, is a major focus of research and development.
Several pipeline drugs, including ALK-001, Etamsylate, Zimura, Visomitin, Elamipretide, Risuteganib, GT005, GEM1003, RPESC-RPE-4W, MA09-hRPE, CPCB-RPE1, OpRegen, and AAVCAGsCD59, are under investigation for their potential in treating AMD. These drugs will be available through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. AMD is also associated with other conditions, such as Glaucoma, Diabetic retinopathy, and Retinopathy of prematurity.
Our age-related macular degeneration market researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The high prevalence of AMD is the key driver of the market. Age-related Macular Degeneration (AMD) is a progressive disease that affects the macula, the central part of the retina, leading to vision loss and eventual blindness. The condition is a significant global health concern, particularly among the geriatric population. According to the World Health Organization, AMD is the leading cause of blindness worldwide, with the highest prevalence among individuals aged 65 and above. Risk factors for AMD include aging, smoking, high cholesterol, and high blood pressure. The disease manifests in two forms: Dry AMD and Wet AMD. Dry AMD is characterized by the presence of drusen, yellow deposits under the retina, while Wet AMD involves the growth of new blood vessels under the retina, leading to leaking and bleeding.
Currently, treatment options for AMD include anti-VEGF intravitreal injections (Eylea, Lucentis, Ranibizumab), photodynamic therapy (PDT), and laser photocoagulation. Regeneron, Novartis, and Roche are some key players in the therapeutics market, with pipeline valuation analysis ongoing for OPT-302, KSI-301, RGX-314, Danicopan, ALXN2040, and EG-301. Unmet needs in AMD treatment include the development of long-lasting therapies, combination therapies, and therapies for Dry AMD. Business possibilities lie in addressing these unmet needs and expanding into emerging markets. Symptoms of AMD include blurred vision, distorted vision, and difficulty recognizing faces. Diagnosis involves a comprehensive eye exam, including a dilated eye exam and imaging tests.
Disease management involves a combination of vitamin supplements, lifestyle changes, and therapeutic interventions. Strategic competitor assessment, market characterization, and clinical trial mapping are essential components of the AMD therapeutics market analysis. Understanding the mechanisms of action of various therapies, including anti-VEGF therapy, is crucial for effective disease management. In conclusion, the AMD market presents significant opportunities for growth, driven by the increasing prevalence of the disease, the unmet needs in treatment, and the ongoing research and development efforts by key players.
The strategic alliances by companies to treat AMD is the upcoming trend in the market. Age-related Macular Degeneration (AMD) is a leading cause of vision loss among the geriatric population, according to the World Health Organization. The disease is characterized by two forms: dry AMD and wet AMD. While there are treatment options such as photodynamic therapy (PDT), laser photocoagulation, and anti-VEGF intravitreal injections using drugs like Eylea (Regeneron), Lucentis (Ranibizumab), Avastin, and Faricimab, unmet needs persist. Companies like Regeneron, Janssen Pharmaceuticals, and Roche are actively investigating new therapies to address these needs. In December 2020, Janssen acquired the rights to Hemera Biosciences' investigational gene therapy HMR59, which aims to preserve vision in late-stage AMD patients.
Other promising drugs in the pipeline include OPT-302, KSI-301, RGX-314, Danicopan, ALXN2040, and EG-301. Strategic competitor assessments, clinical trial mapping, and mechanism of action analyses are crucial for understanding the AMD therapeutics market revenue and treatment usage patterns. Vitamin supplements and lifestyle changes are also essential components of AMD disease management. Business possibilities are vast in this market, with a significant epidemiology and growing demand for effective treatments.
The rising geriatric population is a key challenge affecting the market growth. Age-related Macular Degeneration (AMD) is a leading cause of vision loss among the geriatric population, according to the World Health Organization. While there are treatment options available for the wet form of AMD, such as anti-VEGF intravitreal injections of Eylea (Regeneron), Lucentis (Ranibizumab), Avastin, and Faricimab, no approved drugs exist for the treatment of dry AMD. Dry AMD, characterized by the presence of drusen and RPE degeneration, accounts for approximately 80-90% of AMD cases. Currently, off-label use of drugs like VEGF inhibitors and photodynamic therapy (PDT) with laser photocoagulation are the primary treatment methods for dry AMD. Vitamin supplements, including Vitamin C, Vitamin E, lutein, zeaxanthin, zinc, and copper, are also used to help reduce the risk of vision loss.
However, several drugs, such as OPT-302, KSI-301, RGX-314, Danicopan, ALXN2040, and EG-301, have failed in clinical trials for the treatment of dry AMD. For instance, in 2017, Roche announced that lampalizumab, a monoclonal antibody targeting complement factor D, did not meet the primary endpoint in the Spectri study. The AMD therapeutics market revenue is expected to grow significantly due to the unmet needs and business possibilities in this field. Market characterization, clinical trial mapping, and strategic competitor assessment are crucial for understanding the pipeline valuation analysis and treatment usage patterns. The mechanisms of action and disease management strategies for both dry and wet AMD are essential for developing effective therapeutics.
The age-related macular degeneration market forecasting report includes the adoption lifecycle of the market, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
AbbVie Inc.: The company offers RGX 314, a groundbreaking one-time gene therapy designed to address wet AMD, diabetic retinopathy, and other chronic retinal diseases.
The market research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Age-related Macular Degeneration (AMD) is a leading cause of vision loss among the geriatric population. The AMD market is primarily driven by the development of innovative therapeutics, including anti-VEGF intravitreal injections such as Eylea (Regeneron) and Lucentis (Ranibizumab). These treatments target the VEGF protein, which contributes to the growth of new blood vessels in the retina, a hallmark of wet AMD. Other promising pipeline candidates include OPT-302, KSI-301, RGX-314, Danicopan, ALXN2040, and Eg-301. Photodynamic therapy (PDT) and laser photocoagulation are also used in AMD treatment, while Avastin and Faricimab are off-label uses of anti-VEGF agents. The AMD market valuation analysis reveals significant revenue growth due to the increasing prevalence of both dry and wet AMD.
The unmet needs and business possibilities in this field are vast, with a focus on disease management and improving treatment efficacy. Epidemiology data indicates that AMD affects approximately 196 million people worldwide, with symptoms including blurred vision, distorted vision, and central vision loss. Diagnosis relies on a combination of clinical examination and imaging techniques. Strategic competitor assessment, market characterization, clinical trial mapping, and mechanisms of action are essential aspects of the AMD therapeutics market. In addition to pharmacological interventions, vitamin supplements and lifestyle changes are also recommended for AMD management. The World Health Organization highlights the importance of early detection and intervention to prevent or slow down vision loss.
Market Scope |
|
Report Coverage |
Details |
Page number |
158 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.54% |
Market Growth 2024-2028 |
USD 5.10 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
5.61 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 44% |
Key countries |
US, Germany, UK, France, and Japan |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Adverum Biotechnologies Inc., Alimera Sciences Inc., Alkeus Pharmaceuticals Inc., Amgen Inc., Apellis Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, Bio Thera Bio Pharmaceutical Co. Ltd., Biocon Ltd., F. Hoffmann La Roche Ltd., IVERIC bio Inc., Lupin Ltd., Novartis AG, Outlook Therapeutics Inc., Pfizer Inc., Regeneron Pharmaceuticals Inc., Ribomic Inc., Viatris Inc., and Xbrane Biopharma AB |
Market dynamics |
Parent market analysis, market growth inducers and obstacles, market forecast, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, market condition analysis for the forecast period |
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Type
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.